XML 163 R147.htm IDEA: XBRL DOCUMENT
v3.20.4

Stock-Based Compensation (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | ---
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018
Stock-based compensation | $ 53,000 | $ 63,000 | $ 135,000 | $ 172,000 | $ 206,000 | $ 443,000
Brooklyn Immunotherapeutics, LLC [Member] |  |  |  |  |  |
Stock-based compensation |  |  | $ 68,202 | $ 68,674 |  |

X
- Definition Amount of noncash expense for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_ShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |